Glyfloz-M 10/1000 Tablet ER is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Metformin 1000 mg in an extended-release formulation. It is primarily indicated for the management of type 2 diabetes mellitus to improve glycemic control in adults when diet and exercise alone are insufficient. Dapagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting urinary glucose excretion and thereby lowering blood glucose levels. Metformin, a biguanide, decreases hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity. The extended-release formulation ensures a gradual release of metformin, minimizing gastrointestinal side effects commonly associated with immediate-release forms. Glyfloz-M 10/1000 Tablet ER is typically administered once daily with meals to optimize absorption and tolerability. It is contraindicated in patients with severe renal impairment, acute or chronic metabolic acidosis, and hypersensitivity to its components. Caution is advised in patients with hepatic dysfunction or risk factors for lactic acidosis. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination offers a complementary mechanism of action, providing effective glycemic control while potentially aiding in weight reduction and cardiovascular risk management.